In general, PET imaging targeting PSMA is indicated to assess the presence of metastases in patients with PCa before treatment begins, to evaluate PCa recurrence in patients with high PSA levels after treatment and to determine PSMA expression in cancer cells to guide eligibility for PSMA-targeted therapy. The gene discussed is KLK3; the disease is posterior cortical atrophy.